UNSPSC 51263136: Timolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula 2C13H24N4O3S.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 817W3C6175, chemically known as 2-propanol, 1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)-oxy)-, (+-)- but generally known as timolol, which bears US NIH Compound Identifier 5478. European Medicines Agency schedules Timolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11069MIG.

UNSPSC 51263136 Timolol is a Commodity code that captures pharmaceutical products, specifically beta-blocker ophthalmic medications used to treat glaucoma and ocular hypertension. The recent state and local procurement activity under this code, however, shows a significant mismatch between the code's nominal scope and what is actually being solicited. The only concrete opportunity posting referencing this code — Seminole County, Florida's IFB for Naloxone and Drug Deactivation Systems — involves emergency opioid reversal agents and harm-reduction equipment, not timolol or any glaucoma therapy. The Texas Health and Human Services Commission's RFI regarding direct-to-manufacturer prescription programs is exploratory market research on pharmacy benefit delivery models rather than procurement of a specific pharmaceutical product. State and local jurisdictions issuing under this code appear sparse and geographically dispersed, with Florida and Texas representing the only recent activity visible in the posted opportunities.

Seminole County issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with a response deadline of July 26, 2023, for quarterly delivery to the Seminole County Community Health Building in Sanford, Florida. The contract includes a two-year initial term with a one-year renewal option and requires vendors to cover all shipping and delivery costs. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities regarding direct-to-manufacturer prescription fulfillment for self-insured plans and state agencies, with response deadline the same day. The RFI does not commit to specific contract value or duration but signals the state's intent to develop formal procurement specifications following the information-gathering phase. The code shows little relevant recent activity; state and local procurement professionals evaluating timolol supply opportunities should rely on direct outreach to pharmacy directors and health department procurement offices rather than on UNSPSC-tagged solicitations.